Reducing Barriers to Accessing Administrative Data on SARS-CoV-2 Vaccination for Research

Matthew Herder; Andrew McRae; Patrick Archambault; Patrick Fok; Hana Wiemer; Laurie Morrison

Reducing Barriers to Accessing Administrative Data on SARS-CoV-2 Vaccination for Research

Matthew Herder, Andrew McRae, Patrick Archambault, Patrick Fok, Hana Wiemer, Laurie Morrison

Research output: Contribution to journal › Article › peer-review

Abstract

Public trust in scientific research, especially research regarding vaccines, has proven fragile during the COVID-19 pandemic. To counter abundant misinformation about SARS-CoV-2 vaccines, rigorous, ongoing evaluations of vaccine safety and effectiveness by independent Canadian researchers are important. However, researchers' efforts to conduct timely, national studies of vaccine effectiveness have been hindered by barriers to data sharing that have made it difficult to integrate patients' vaccination status into SARS-CoV-2 clinical and epidemiological studies. Here, McRae et al discuss how a risk-averse data-sharing culture has led to missed opportunities to conduct robust, timely, pan-Canadian SARS-CoV-2 clinical and vaccine effectiveness studies, and outline mechanisms for data sharing that can and should be undertaken.

Original language	Canadian English
Pages (from-to)	943-947
Journal	CMAJ. Canadian Medical Association Journal
Volume	194
Issue number	27
Publication status	Published - Jan. 1 2022

Keywords

Canadian Government
Epidemiology & Epidemiological Methods
Health Policy
Health Services
Infectious Diseases: COVID-19

Disciplines

Health Law and Policy
Law
Medical Jurisprudence
Science and Technology Law

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Reducing Barriers to Accessing Administrative Data on SARS-CoV-2Final published version, 108 KBLicence: Unspecified

Cite this

@article{ded302f5e84349d88b6199d60dc6e66a,

title = "Reducing Barriers to Accessing Administrative Data on SARS-CoV-2 Vaccination for Research",

abstract = " Public trust in scientific research, especially research regarding vaccines, has proven fragile during the COVID-19 pandemic. To counter abundant misinformation about SARS-CoV-2 vaccines, rigorous, ongoing evaluations of vaccine safety and effectiveness by independent Canadian researchers are important. However, researchers' efforts to conduct timely, national studies of vaccine effectiveness have been hindered by barriers to data sharing that have made it difficult to integrate patients' vaccination status into SARS-CoV-2 clinical and epidemiological studies. Here, McRae et al discuss how a risk-averse data-sharing culture has led to missed opportunities to conduct robust, timely, pan-Canadian SARS-CoV-2 clinical and vaccine effectiveness studies, and outline mechanisms for data sharing that can and should be undertaken.",

keywords = "Canadian Government, Epidemiology \& Epidemiological Methods, Health Policy, Health Services, Infectious Diseases: COVID-19",

author = "Matthew Herder and Andrew McRae and Patrick Archambault and Patrick Fok and Hana Wiemer and Laurie Morrison",

note = "Andrew D McRae et al, {"}Reducing Barriers to Accessing Administrative Data on SARS-CoV-2 Vaccination for Research{"} (2022) 194:27 CMAJ 943.",

year = "2022",

month = jan,

day = "1",

language = "Canadian English",

volume = "194",

pages = "943--947",

number = "27",

}

TY - JOUR

T1 - Reducing Barriers to Accessing Administrative Data on SARS-CoV-2 Vaccination for Research

AU - Herder, Matthew

AU - McRae, Andrew

AU - Archambault, Patrick

AU - Fok, Patrick

AU - Wiemer, Hana

AU - Morrison, Laurie

N1 - Andrew D McRae et al, "Reducing Barriers to Accessing Administrative Data on SARS-CoV-2 Vaccination for Research" (2022) 194:27 CMAJ 943.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Public trust in scientific research, especially research regarding vaccines, has proven fragile during the COVID-19 pandemic. To counter abundant misinformation about SARS-CoV-2 vaccines, rigorous, ongoing evaluations of vaccine safety and effectiveness by independent Canadian researchers are important. However, researchers' efforts to conduct timely, national studies of vaccine effectiveness have been hindered by barriers to data sharing that have made it difficult to integrate patients' vaccination status into SARS-CoV-2 clinical and epidemiological studies. Here, McRae et al discuss how a risk-averse data-sharing culture has led to missed opportunities to conduct robust, timely, pan-Canadian SARS-CoV-2 clinical and vaccine effectiveness studies, and outline mechanisms for data sharing that can and should be undertaken.

AB - Public trust in scientific research, especially research regarding vaccines, has proven fragile during the COVID-19 pandemic. To counter abundant misinformation about SARS-CoV-2 vaccines, rigorous, ongoing evaluations of vaccine safety and effectiveness by independent Canadian researchers are important. However, researchers' efforts to conduct timely, national studies of vaccine effectiveness have been hindered by barriers to data sharing that have made it difficult to integrate patients' vaccination status into SARS-CoV-2 clinical and epidemiological studies. Here, McRae et al discuss how a risk-averse data-sharing culture has led to missed opportunities to conduct robust, timely, pan-Canadian SARS-CoV-2 clinical and vaccine effectiveness studies, and outline mechanisms for data sharing that can and should be undertaken.

KW - Canadian Government

KW - Epidemiology & Epidemiological Methods

KW - Health Policy

KW - Health Services

KW - Infectious Diseases: COVID-19

UR - https://digitalcommons.schulichlaw.dal.ca/scholarly_works/1100

M3 - Article

SN - 0820-3946

VL - 194

SP - 943

EP - 947

JO - CMAJ. Canadian Medical Association Journal

JF - CMAJ. Canadian Medical Association Journal

IS - 27

ER -

Reducing Barriers to Accessing Administrative Data on SARS-CoV-2 Vaccination for Research

Abstract

Keywords

Disciplines

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this